Uncovering the ultra‐frail: A distinct subgroup in non‐transplant eligible newly diagnosed patients with multiple myeloma, with an inferior clinical outcome
HemaSphere · 2025-12 · 9 (12)
DOI: 10.1002/hem3.70268 ↗Kurz gefasst
Leserbrief in der Zeitschrift HemaSphere, online erschienen am 08.12.2025. Verfasst von Kazimierz Groen und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Amsterdam UMC Vrije Universiteit Amsterdam Amsterdam The Netherlands. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Non-transplant eligible patients with newly diagnosed multiple myeloma (NTE-NDMM) who are categorized as frail according to the International Myeloma Working Group Frailty Index (IMWG-FI) show pronounced heterogeneity in clinical characteristics, leading to differences in frailty scores-ranging from 2 to 5-based on the type and number of geriatric impairments and comorbidities.As a result, clinical outcomes may differ markedly within this subgroup.1 Indeed, a post hoc analysis of the HOVON-123 trial, in which patients were treated with nine cycles of dose-adjusted melphalan, prednisone, and bortezomib, revealed that the overall survival (OS) of frail patients with an IMWG-FI of 2 had an OS comparable to intermediate-fit patients and superior to frail patients with scores of 3-5.In addition, treatment discontinuation after 9 months was considerably higher in patients with higher frailty scores. 2 Accordingly, in the IFM 2017-03 trial, in which daratumumab-lenalidomide was compared with lenalidomide-dexamethasone, progression free survival (PFS) was significantly prolonged in patients with a frailty score of 2 compared to those with scores of 4-5. 3 Notably, a similar frailty score may capture distinct aging phenotypes: for example a score of 2 may solely result from advanced age or may reflect significant geriatric impairments in a younger individual.To address this heterogeneity, frail patients may be more rationally stratified based on the underlying drivers of frailty, yielding three frail subgroups: frail-by-age (>80 years, no comorbidities or impairments in [I]ADL), frail-byimpairments (≤80 years, with comorbidities and/or impairments in [I] ADL), and ultra-frail (>80 years, with comorbidities and/or impairments in [I]ADL).The prognostic impact of these three distinct frailty subgroups on OS has been variably reported.In the HOVON-143HemaSphere.
Autor:innen und Institutionen
- Department of Hematology, Amsterdam UMC Vrije Universiteit Amsterdam Amsterdam The Netherlands.
- Cancer Center Amsterdam Treatment and Quality of life Amsterdam The Netherlands.
- Department of Hematology Haga Hospital The Hague The Netherlands.
- HOVON Foundation Rotterdam The Netherlands.
- Department of Hematology Erasmus MC Cancer Institute Rotterdam The Netherlands.
- Department of Internal Medicine Albert Schweitzer Hospital Dordrecht The Netherlands.
ORCID-Profile: Kazimierz Groen, Febe Smits, Maarten R Seefat, Niels W C J van de Donk
Zitieren
APA
Groen, K., Smits, F., Nasserinejad, K., Levin, M. D., Regelink, J. C., Timmers, G. J., de Waal, E. G. M., Westerman, M., Velders, G. A., de Heer, K., Leys, R. B. L., van Kampen, R. J. W., Stege, C. A. M., Seefat, M. R., Nijhof, I. S., van der Spek, E., Klein, S. K., van de Donk, N. W. C. J., Ypma, P. F., & Zweegman, S. (2025). Uncovering the ultra‐frail: A distinct subgroup in non‐transplant eligible newly diagnosed patients with multiple myeloma, with an inferior clinical outcome. HemaSphere, 9(12). https://doi.org/10.1002/hem3.70268
Vancouver
Groen K, Smits F, Nasserinejad K, Levin MD, Regelink JC, Timmers GJ, et al. Uncovering the ultra‐frail: A distinct subgroup in non‐transplant eligible newly diagnosed patients with multiple myeloma, with an inferior clinical outcome. HemaSphere. 2025;9(12). doi:10.1002/hem3.70268
BibTeX
@article{Groen2025,
author = {Groen, Kazimierz and Smits, Febe and Nasserinejad, Kazem and Levin, Mark-David and Regelink, Josien C and Timmers, Gert-Jan and de Waal, Esther G M and Westerman, Matthijs and Velders, Gerjo A and de Heer, Koen and Leys, Rineke B L and van Kampen, Roel J W and Stege, Claudia A M and Seefat, Maarten R and Nijhof, Inger S and van der Spek, Ellen and Klein, Saskia K and van de Donk, Niels W C J and Ypma, Paula F and Zweegman, Sonja},
title = {Uncovering the ultra‐frail: A distinct subgroup in non‐transplant eligible newly diagnosed patients with multiple myeloma, with an inferior clinical outcome},
journal = {HemaSphere},
year = {2025},
volume = {9},
number = {12},
doi = {10.1002/hem3.70268}
}
EUVIMED